Fluidnet Corp., a New Hampshire developer of intravenous fluid pumps, has appointed Benjamin Bulkley as president and CEO of the company. Bulkley has begun working in the position and follows previous CEO Jeffrey Carlisle, who will serve as chief innovation officer at Fluidnet.
Bulkley joins Fluidnet  from his previous post as chief operating officer of Allscripts, a Chicago-based, healthcare-focused software provider. Prior to that, he led global commercial operations at Invitrogen Corp. (now Life Technologies Corp.) and headed up the global services business at General Electric Company’s healthcare IT division. Bulkley earned a master’s degree in systems engineering from Gannon University and a bachelor’s degree in electrical engineering from the University of Connecticut.
In March, Fluidnet closed a Series B funding round  of about $9 million – $17 million, including a small bridge loan raised in 2009.
Fluidnet is preparing to submit a 510(k) pre-market notice to the U.S. Food and Drug Administration for its advanced IV infusion system.
Founded in 2002, Fluidnet has its headquarters in Portsmouth, N.H., with its laboratory facility in Amesbury.